STRATEGYMD
The Capability Analytics Company

- How prepared is your organization for Regulation changes?
- How will your organization capitalize on scientific disruptions?
- How scalable and repeatable are your laboratory and operational standards?

Getting the Right people, focused on the Right decisions, at the Right time!

Why We Do IT

StrategyMD™ leverages a unique quantitative approach and an obsessive group of 20+ year seasoned consultants and C-Level executives to lead quality transformations using our Wheel below with our 4 building blocks.

We do not try to be all things to all clients, we pride ourselves on listening to your needs and providing outcomes that grow your business, and if we can't do the work we will find someone who can. The people you meet are the people that do the work. We are refreshingly priced because, we do things in real-time (5-10 days) vs. consulting time (4-6 weeks) leveraging our proprietary software resulting in an average of 30% bottom line impact.

Life Sciences Focus

Developing the right mechanisms, systems and tools for strategic development and implementation is critical to the success of any Life Sciences organization. Today's competitive climate is compounded by mounting FDA pressures and the complexity of manufactured therapies that drive patient & societal care. This type of rapid transformation requires that organizations continuously improve research and laboratory outcomes while simultaneously managing operational costs. Those Life Sciences organizations that can rapidly reduce these competing responsibilities while improving quality of your clinical pipeline will win. Building the correct therapies that will transform medicine can only be accomplished through aligning process, technology and then people.

CapabilityAnalytics™ (CA) provides a distinct view of a Life Sciences organization by what it does — through capability models. Organizations use this perspective to develop a common understanding of medicinal priorities, holistic taxonomy, ethical standards, and actionable change mandates that can drive both sides of your balance sheet - either by reducing and/or containing production and commercialization costs and/or improving the value of manufactured therapies through technology, quality improvements, and innovation.

DetectabilityAnalytics™ (DA) Leverages Failure Mode and Effects Analysis (FMEA) as a platform for intensive process review resulting in identification and prioritization of failure modes across the value stream. DA provides a distinct view by detecting the severity and probability of operational, technical and process defects, gaps and errors. Understanding causation provides the enterprise with a roadmap to optimize and increase operational diligence, profitability, and cash flow.

www.strategymd.com / 617-784-3889